Mode
Text Size
Log in / Sign up

Ugandan malaria patients with PfKelch13 mutant parasites showed no increased gametocyte production or mosquito transmissionUganda Malaria Study: Does Resistance Stop Spreading?

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note no evidence that PfKelch13 mutations increase gametocyte production or mosquito transmission in this Ugandan cohort.

This cohort study investigated uncomplicated P. falciparum infections in 235 patients at Kalongo Hospital in northern Uganda. Researchers characterized parasites for PfKelch13 mutations (C469Y or A675V) and compared them to wild-type strains. The primary focus was on gametocyte production and infectivity, alongside secondary outcomes including mutation carriage, parasite abundance, and mosquito infection rates.

Detection of PfKelch13 mutations varied by assay, with sequencing identifying mutations in 35.8% of infections (78/218) and ddPCR detecting them in 59.1% of infections (136/230). Microscopy identified gametocyte carriage in 24.0% of patients (56/233), while qRT-PCR detected it in 56.6% (133/235). Mosquito infection rates were observed in 1.4% of cases (120/8745). Detection of mutations in field-caught mosquito bloodmeals occurred in 40.1% (21/52) and sporozoite-positive mosquitoes in 28.0% (7/25).

Statistical analysis revealed no association between gametocyte carriage and the abundance of PfKelch13 mutant parasites (p=0.603). Mosquito infection rates were positively associated with gametocyte density (beta = 0.39; 95% CI = 0.23-0.59, p < 0.001), but no interaction was observed between mosquito infection rates and mutant parasite abundance (p = 0.452). Safety data, including adverse events and tolerability, were not reported. The study concludes there is no evidence that artemisinin resistance affected gametocyte production or transmission to mosquitoes, though the implications for ART-R remain unclear.

Malaria is a huge problem in many parts of Africa. In northern Uganda, it affects thousands of people every year. The main worry is that these resistant parasites might be getting stronger.

If the parasites can hide from the medicine, they stay in the patient longer. The fear is that they might also become better at jumping to mosquitoes. If they jump to mosquitoes more easily, the disease could spread faster and become much harder to control.

Doctors need to know if these resistant parasites are dangerous for the community. Right now, the answer is not clear. That is why this new study is so important.

In the past, scientists thought that if a parasite survived medicine, it might also become a better flyer. They worried that the two traits were linked.

But here is the twist. This new research shows that the parasites are not becoming better at spreading. They are just surviving the medicine. The ability to jump to a mosquito is separate from the ability to hide from drugs.

Think of the parasite like a car with two engines. One engine helps it survive medicine. The other engine helps it fly to a mosquito.

Scientists used to think that fixing one engine might break the other. They worried that a car that survived medicine might also have a faster flying engine. This new study shows that the engines work independently. A car can have a strong survival engine without having a fast flying engine.

Researchers looked at 235 people who had malaria at Kalongo Hospital in northern Uganda. They checked the blood of these patients for specific genetic changes that show resistance.

They also counted how many parasites were ready to fly to mosquitoes. They even let real mosquitoes bite the patients to see if the parasites could infect them. This gave them a real-world look at how the disease spreads.

The study found that resistant parasites are very common. About 36% of the infections had these genetic changes. When scientists looked closely, they found that having these changes did not change how many parasites were ready to fly.

The most important finding is about the mosquitoes. Only a small number of mosquitoes got infected. The study showed that the number of parasites ready to fly was the main factor. The resistance genes did not make the mosquitoes more likely to get infected.

But there's a catch. This is where things get interesting. While the parasites are common, the study was done in one specific area. We need to see if this holds true everywhere.

Scientists say this is good news for malaria control. It means current medicines might still work as planned. The parasites are not evolving into a super-virus that spreads faster.

However, experts warn that we must keep watching. If the parasites keep surviving medicine, they might eventually become fully resistant. Then, the current medicines might stop working completely.

If you live in an area with malaria, this news is reassuring. It suggests that the medicine you take is still effective. You do not need to worry that the disease is spreading faster because of these genetic changes.

Still, it is important to finish your full course of medicine. Stopping early helps the parasites learn to survive. This study shows that survival does not mean faster spread, but we must not let the parasites learn to survive.

This study was done in northern Uganda. We do not know if the same results happen in other countries. Also, the study looked at uncomplicated malaria, which is the mild form. It did not look at severe cases.

More research is needed to confirm these results in other places. Scientists will continue to monitor the parasites as they travel to new areas.

The goal is to keep medicines working for as long as possible. If the parasites stay separate from the spreading ability, we have a better chance of winning this fight. We just need to stay patient and keep testing.

Study Details

Study typeCohort
Sample sizen = 235
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
Background: Partial resistance to artemisinins (ART-R) has emerged in East Africa, associated with mutations in the Plasmodium falciparum kelch13 gene. It is currently unclear whether ART-R has implications for gametocyte production or for onward transmission to mosquitoes. Methods: In a cohort of uncomplicated malaria patients attending Kalongo Hospital in northern Uganda, we quantified carriage of PfKelch13 mutant parasites by conventional sequencing and droplet digital PCR (ddPCR) for the C469Y and A675V mutations. Prevalence and density of gametocytes and ring-stage parasites were assessed by microscopy and quantitative reverse-transcriptase PCR (qRT-PCR). Lumefantrine concentrations, indicative of prior malaria treatment, were determined by ultra-high performance liquid chromatography-tandem mass spectrometry. Transmission potential of wild-type and PfKelch13 mutant parasites was assessed by mosquito feeding assays and complemented with molecular characterization of parasites in wild-caught mosquitoes from household resting catches. Findings: We enrolled 235 patients with symptomatic P. falciparum infection; PfKelch13 C469Y or A675V mutations were detected in 35.8% (78/218) of infections by sequencing and 59.1% (136/230) by ddPCR. Gametocyte carriage was 24.0% (56/233) by microscopy and 56.6% (133/235) by qRT-PCR and not associated with the abundance of PfKelch13 mutant parasites by ddPCR (p=0.603). Among a total of 227 mosquito feeds with patient whole blood, 1.4% (120/8745) of mosquitoes became infected. Mosquito infection rates were positively associated with gametocyte density ({beta} = 0.39, 95% CI = 0.23-0.59, p < 0.001) without an observed interaction with the abundance of PfKelch13 mutant parasites (p = 0.452). PfKelch13 C469Y or A675V mutations were detected in 40.1% (21/52) of malaria-infected bloodmeals of field-caught mosquitoes and in 28.0% (7/25) of sporozoite-positive mosquitoes. Interpretation: We conclude that pfkelch13 mutations are very common in patients in northern Uganda with uncomplicated malaria, mostly in multiclonal infections. We observed no evidence that ART-R affected gametocyte production or transmission to mosquitoes. Funding: Dutch Research Council (NWO)
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.